Estrone sulfate potassium

Names

[ Name ]:
Estrone sulfate potassium

[Synonym ]:
potassium,[(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate

Biological Activity

[Description]:

Estrone sulfate potassium is a natural endogenous steroid and is an estrogen ester and conjugate[1].

[Related Catalog]:

Research Areas >> Others

[References]

[1]. O'Neil MM, et al. Differential Regulation of Gonadotropins in Response to Continuous Infusion of Native Gonadotropin-Releasing Hormone in the Winter Anovulatory Mare and Effects of Treatment With Estradiol-17β. J Equine Vet Sci. 2019 Apr;75:93-103.

Chemical & Physical Properties

[ Molecular Formula ]:
C₁₈H₂₁KO₅S

[ Molecular Weight ]:
389.52800

[ Exact Mass ]:
389.08300

[ PSA ]:
89.05000

[ LogP ]:
4.37420

[ Appearance of Characters ]:
off-white to light tan

[ Storage condition ]:
−20°C

Safety Information

[ Symbol ]:

GHS07, GHS08

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H319-H335-H361

[ Precautionary Statements ]:
P261-P281-P305 + P351 + P338

[ Hazard Codes ]:
Xi: Irritant;

[ Risk Phrases ]:
36/37/38

[ Safety Phrases ]:
26-36

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
2

Articles

Major active components in grapefruit, orange, and apple juices responsible for OATP2B1-mediated drug interactions.

J. Pharm. Sci. 102(1) , 280-8, (2013)

We aimed to explore the major active components in grapefruit juice (GFJ), orange juice (OJ), and apple juice (AJ) that are responsible for OATP2B1-mediated drug interactions, by means of in vitro stu...

Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins.

Eur. J. Pharm. Sci. 47(1) , 244-55, (2012)

To support drug development, the drug-drug interaction potential (DDI) of an investigational drug (AZX) was assessed against the probe estradiol 17β-glucuronide as well as against simvastatin acid, at...

Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.

Eur. J. Cancer 50(6) , 1055-64, (2014)

Recent data have raised concern about the clinical efficacy of aromatase inhibitors in overweight and/or obese breast cancer patients. We report in vivo aromatase inhibition and plasma and tissue oest...